DolPHIN-2 Final Results: More Rapid Virologic Suppression With DTG- vs EFV-Based ART Started in Late Pregnancy Through 72 Wks Postpartum

March 6-10, 2021; Virtual
Superior virologic efficacy observed with DTG-based regimen vs EFV-based regimen throughout pregnancy and through the breastfeeding period: final results of the DolPHIN-2 study.
Format: Microsoft PowerPoint (.ppt)
File Size: 181 KB
Released: March 10, 2021

Acknowledgements

Provided by Clinical Care Options, LLC.

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Gilead Sciences
Janssen Therapeutics, Division of Janssen Products, LP
Merck Sharp & Dohme Corp.
ViiV Healthcare

Related Content

An expert panel of healthcare professionals and patient advocates discuss barriers faced by aging patients with HIV, from Clinical Care Options (CCO)

Jonathan Appelbaum, MD, FACP, AAHIVS
Program Director
Lydia Mungherera, MBChB Cristina Mussini, MD Dorothy Onyango Melanie Reese Marc Thompson
Released: September 23, 2022

Expert analysis of barriers and solutions to PrEP uptake in key populations

Milena Murray, PharmD, MSc, BCIDP, AAHIVP, FCCP
Program Director
Released: September 23, 2022

Expert analysis of barriers and solutions to PrEP uptake in key populations

Jeffrey Kwong, DNP, MPH, FAANP, FAAN
Program Director
Released: September 22, 2022

Clinical Care Options (CCO) expert analysis of new data from AIDS 2022, provided by expert HIV faculty

Chloe Orkin Photo Chloe Orkin, MBChB, FRCP, MD Released: September 20, 2022

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings